Comparison · NCT04211337-sae
Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): serious adverse events. Trial comparisons, record NCT04211337-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04211337-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.223 | 0.17 | 0.287 | wilson | |
| Risk in group 2 | 0.278 | 0.199 | 0.375 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.165 | 0.0463 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.8 | 0.529 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.743 | 0.425 | 1.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Selpercatinib - Treatment A (TRT A) than on Cabozantinib or Vandetanib - Treatment B (TRT B) | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Selpercatinib - Treatment A (TRT A) | 160 milligrams Selpercatinib administered orally (PO) twice daily (BID). Adolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID). | 43 | 193 | EG000 |
| Group 2 | Cabozantinib or Vandetanib - Treatment B (TRT B) | 140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.~Cabozantinib Adolescent Dose: 40 mg/m2.~Vandetanib Adolescent Dose:~0.7 - \<0.9 - 100 mg every other day (QOD) 0.9 - \<1.2 - 100 mg QD 1.2 - \<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg~≥1.6 - 200 QD | 27 | 97 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to 39 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- NCT number
- NCT04211337
- Phases
- PHASE3
- Conditions
- Medullary Thyroid Cancer
- Interventions
- Selpercatinib, Cabozantinib, Vandetanib
- Lead sponsor
- Loxo Oncology, Inc.
- Results first posted
- 2024-06-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04211337?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04211337-sae